BRPI0513351A - métodos para inibir metástase de tumor, e inibir adesão de célula de tumor às células endotelias e/ou inibir a permeabilidade capilar na forma de migração transendotelial de células de tumor, método de triagem para um inibidor da permeabilidade capilar para células de tumor, e, uso de um antagonista de leucotrieno ou um sal do mesmo farmaceuticamente aceitável - Google Patents

métodos para inibir metástase de tumor, e inibir adesão de célula de tumor às células endotelias e/ou inibir a permeabilidade capilar na forma de migração transendotelial de células de tumor, método de triagem para um inibidor da permeabilidade capilar para células de tumor, e, uso de um antagonista de leucotrieno ou um sal do mesmo farmaceuticamente aceitável

Info

Publication number
BRPI0513351A
BRPI0513351A BRPI0513351-3A BRPI0513351A BRPI0513351A BR PI0513351 A BRPI0513351 A BR PI0513351A BR PI0513351 A BRPI0513351 A BR PI0513351A BR PI0513351 A BRPI0513351 A BR PI0513351A
Authority
BR
Brazil
Prior art keywords
inhibiting
capillary permeability
tumor cell
tumor
cells
Prior art date
Application number
BRPI0513351-3A
Other languages
English (en)
Inventor
Masako Nozaki
Original Assignee
Inflammation Res Ct Company Lt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflammation Res Ct Company Lt filed Critical Inflammation Res Ct Company Lt
Publication of BRPI0513351A publication Critical patent/BRPI0513351A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODOS PARA INIBIR METáSTASE DE TUMOR, E INIBIR A ADESãO DE CéLULA DE TUMOR àS CéLULAS ENDOTELIAIS E/OU INIBIR A PERMEABIILIDADE CAPILAR NA FORMA DE MIGRAçãO TRANSENDOTELIAL DE CéLULAS DE TUMOR. MéTODO DE TRIAGEM PARA UM INIBIDOR DA PERMEABILIDADE CAPILAR PARA CéLULAS DE TUMOR, E, USO DE UM ANTAGONISTA DE LEUCOTRIENO OU UM SAL DO MESMO FARMACEUTICAMENTE ACEITáVEL. Um antagonista de leucotrieno C4 e D4 é usados para inibir a metástase de tumor pela ação para inibir a adesão de célula de tumor às células endoteliais, impedindo deste modo o extravasamento de célula de tumor.
BRPI0513351-3A 2004-07-14 2005-07-14 métodos para inibir metástase de tumor, e inibir adesão de célula de tumor às células endotelias e/ou inibir a permeabilidade capilar na forma de migração transendotelial de células de tumor, método de triagem para um inibidor da permeabilidade capilar para células de tumor, e, uso de um antagonista de leucotrieno ou um sal do mesmo farmaceuticamente aceitável BRPI0513351A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58750704P 2004-07-14 2004-07-14
PCT/US2005/024937 WO2006019874A1 (en) 2004-07-14 2005-07-14 Method for inhibiting tumor metastasis

Publications (1)

Publication Number Publication Date
BRPI0513351A true BRPI0513351A (pt) 2008-05-06

Family

ID=35907711

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513351-3A BRPI0513351A (pt) 2004-07-14 2005-07-14 métodos para inibir metástase de tumor, e inibir adesão de célula de tumor às células endotelias e/ou inibir a permeabilidade capilar na forma de migração transendotelial de células de tumor, método de triagem para um inibidor da permeabilidade capilar para células de tumor, e, uso de um antagonista de leucotrieno ou um sal do mesmo farmaceuticamente aceitável

Country Status (10)

Country Link
US (3) US20080206203A1 (pt)
EP (2) EP1997491B1 (pt)
JP (1) JP3983272B2 (pt)
KR (1) KR101213926B1 (pt)
CN (2) CN102847155B (pt)
AT (1) ATE481968T1 (pt)
BR (1) BRPI0513351A (pt)
DE (1) DE602005023797D1 (pt)
HK (2) HK1174533A1 (pt)
WO (1) WO2006019874A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014175253A1 (ja) 2013-04-22 2014-10-30 株式会社栃木臨床病理研究所 抗腫瘍剤
TWI626046B (zh) * 2015-10-06 2018-06-11 高雄醫學大學 用於預防或治療肺癌的醫藥組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528060A (en) 1982-07-08 1985-07-09 Hercules Incorporated Apparatus for winding of filamentary composites
US4720505A (en) * 1983-06-27 1988-01-19 Merck Frosst Canada, Inc. Leukotriene antagonists
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
JPS63258854A (ja) 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
JPS63258879A (ja) 1987-04-16 1988-10-26 Mitsubishi Kasei Corp ビニルチアゾ−ル誘導体およびそれを有効成分とするロイコトリエン拮抗剤
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
JPH02169583A (ja) 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
US5079261A (en) 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
GB9119001D0 (en) 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
US5428060A (en) * 1992-08-27 1995-06-27 Merck Frosst Canada, Inc. Heteroarylnaphthalene lactones as inhibitors of leukotriene biosynthesis
JPH06116163A (ja) * 1992-10-05 1994-04-26 Toagosei Chem Ind Co Ltd 腫瘍抑制剤
DE4424714A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff
US5552437A (en) * 1994-10-27 1996-09-03 Merck Frosst Canada, Inc. Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
US5527827A (en) * 1994-10-27 1996-06-18 Merck Frosst Canada, Inc. Bisarylcarbinol cinnamic acids as inhibitors of leukotriene biosynthesis
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
ES2191101T3 (es) 1995-06-12 2003-09-01 Ono Pharmaceutical Co Granulos que contienen pranlukast, procedimiento de produccion de los granulos y procedimiento de reduccion de la cohesion del pranlukast.
GB9525261D0 (en) * 1995-12-11 1996-02-07 Bayer Ag Carbamic acid derivatives
US6207654B1 (en) * 1996-05-03 2001-03-27 Bashir Zikria Capillary membrane stabilization and reduction of inflammation during the course of chemotherapy or antiviral treatment through the use of biodegradable macromolecules and interleukin-2
US5911776A (en) 1996-12-18 1999-06-15 Unisys Corporation Automatic format conversion system and publishing methodology for multi-user network
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU746130B2 (en) * 1997-02-05 2002-04-18 University Of Wales College Of Medicine Measurement of plasma volume
KR100547506B1 (ko) 1997-09-26 2006-06-22 코와 가부시키가이샤 테트라졸유도체
WO1999021007A1 (en) 1997-10-23 1999-04-29 Pharmaprint, Inc. Pharmaceutical grade echinacea
EP1077936B1 (en) 1998-05-15 2005-10-05 University Of Vermont Novel analogs of 16-hydroxyeicosatetraenoic acid
DE19834713A1 (de) * 1998-07-31 2000-02-03 Boehringer Ingelheim Pharma Neue Phenylethylaminderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6221880B1 (en) 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
EP1119372A1 (en) * 1998-10-09 2001-08-01 Schering Corporation Composition and method for treating allergic diseases
US6194432B1 (en) 1998-10-13 2001-02-27 Fred D. Sheftell Prevention and treatment of migraine, cluster and other recurrent headaches using leukotriene antagonist drugs
AUPP910699A0 (en) * 1999-03-10 1999-04-01 Pharmalink International Limited Inhibitor of lipoxygenase pathways
CA2378880C (en) * 1999-07-21 2010-02-23 Omeros Medical Systems, Inc. Solutions and methods for inhibition of pain, inflammation and cartilage degradation
KR100381834B1 (ko) * 2000-05-20 2003-04-26 이상득 용출성이 개선된 프란루카스트 고체분산체 조성물 및 그제조 방법
DE10052658A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Pyranosidderivate
DE10052333A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Sulfooxybenzamide
US7148248B2 (en) * 2002-11-29 2006-12-12 Masako Nozaki Method of treating or inhibiting the development of brain inflammation and sepsis
EP1424101A3 (en) * 2002-11-29 2004-08-18 NOZAKI, Masako Use of a leukotriene C4 and D4 receptor antagonist for the preparation of a medicament for treating or preventing brain inflammation and sepsis

Also Published As

Publication number Publication date
CN101022796B (zh) 2013-02-27
EP1765333A4 (en) 2008-06-18
EP1997491B1 (en) 2010-09-22
WO2006019874A1 (en) 2006-02-23
DE602005023797D1 (de) 2010-11-04
US20170014384A1 (en) 2017-01-19
JP2007514002A (ja) 2007-05-31
US20080206203A1 (en) 2008-08-28
EP1765333A1 (en) 2007-03-28
ATE481968T1 (de) 2010-10-15
US20190060278A1 (en) 2019-02-28
HK1108118A1 (en) 2008-05-02
HK1174533A1 (en) 2013-06-14
KR20070051855A (ko) 2007-05-18
EP1997491A1 (en) 2008-12-03
CN101022796A (zh) 2007-08-22
KR101213926B1 (ko) 2012-12-18
CN102847155A (zh) 2013-01-02
JP3983272B2 (ja) 2007-09-26
CN102847155B (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
BRPI0507891A (pt) modulação dos processos inflamatório e metastático
BRPI0518910A2 (pt) modelo fÍsico de rocha anisotràpica integrada
NO20082813L (no) Nedihullsverktoy
BRPI0811382A2 (pt) "anticorpos anti-notch1 nrr isolados, polinucleotídeo, vetor, célula hospedeira, método para produzir um anticorpo anti-notch1 nrr, uso do anticorpo anti-notch1 nrr e composição"
ATE534287T1 (de) Indikatorgranulat
EA200702141A1 (ru) Система и способ создания пакеров в стволе скважины
DE502005007765D1 (de) Entgratmesser zum Entgraten von Bohrungsrändern
EA200801072A1 (ru) Закупоривающий агент на основе воска высокой плотности, предназначенный для подавления притока в скважину
BRPI0513351A (pt) métodos para inibir metástase de tumor, e inibir adesão de célula de tumor às células endotelias e/ou inibir a permeabilidade capilar na forma de migração transendotelial de células de tumor, método de triagem para um inibidor da permeabilidade capilar para células de tumor, e, uso de um antagonista de leucotrieno ou um sal do mesmo farmaceuticamente aceitável
BRPI0418995A (pt) método para a inibição hidratação de argilas nas operações de perfuração, e, fluido de perfuração com base aquosa
Walter et al. Simulated water sources and effects of pumping on surface and ground water, Sagamore and Monomoy flow lenses, Cape Cod, Massachusetts
DE502006003030D1 (de) Verwendung von inhibitoren des na+/h+ austauschers, subtyp 5 (nhe5) zur gedächtnisverbesserung
Anderson et al. Culvert effects on stream and stream-side salamander habitats
BR112017019074A2 (pt) sistema para pré-tratamento e injeção de água do mar e uso de água do mar tratada
AR051273A1 (es) Procedimiento para la intercepcion y conexion de formaciones subterraneas y procedimiento para la produccion y/o inyeccion de hidrocarburos a traves de la conexion de formaciones subterraneas
PT9791T (pt) Deposito tipo estanque, em particular para uso na construcao civil
WO2004091925A8 (en) Method for improving the ozone stability of an inkjet recording element
SE0400753D0 (sv) Betongavverkningsmaskin
NO20070350L (no) Bygningselement
Goula LANDSCAPE AGENCY: WHAT IS A RESPONSIBLE UNDERSTANDING OF THE COAST TODAY?
Batchelor et al. An occurrence of Palaeohelcura tridactyla in the Arbuthnott–Garvock Group, Lower Devonian, at Friarton Quarry, Perth
CN205521879U (zh) 道路护栏预制模板
Huff Relation between Aquifer Mineralogy and the Tendency toward Scale Deposit Formation during Desalination–Examples from Saline Waters in New Mexico
McIntosh et al. Modeling variable-density fluid flow and solute transport in glaciated sedimentary basins
Kapur et al. Microfossil assemblage from a Late Cretaceous intertrappean locality near Manawar, Madhya Pradesh, central India

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: REFERENTE AO DESPACHO 15.24 PUBLICADO NA RPI NO 1997 DE 14/04/2009

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECO A PETICAO NO 020090020344 DE 02/03/2009 , COM BASE NO DISPOSTO NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE O INTERESSADO NAO TEM LEGITIMIDADE PARA O ATO.

B25A Requested transfer of rights approved

Owner name: MASAKO NOZAKI (JP)

Free format text: TRANSFERIDO DE: INFLAMMATION RESEARCH CENTER COMPANY LTD.

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.